Physician profile
Anibal Loza
NPI 1932319738
$1,060.21
in general payments reported to CMS, 2019-2025
11 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $134 · 2021: $249 · 2024: $237 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $159.84 | 2024-2025 | Infinity, Mild Device Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.03 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $125.08 | 2024-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $125.00 | 2021 | |
| Nevro Corp. | $123.95 | 2021 | |
| Amarin Pharma, INC. | $120.82 | 2020 | |
| Novartis Pharmaceuticals Corporation | $115.26 | 2019 | |
| Amgen INC. | $66.02 | 2020-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $38.99 | 2025 | |
| Abbott Laboratories | $23.94 | 2024 | Freestyle Libre 3 |
| Eisai INC. | $19.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anibal Loza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.